Piramal Pharma Consumer Products Division unveils D2C platform Wellify.in
The platform will offer free home delivery, no minimum order value, and delightful offers which will enable rise in daily orders.
Advertisement
Mumbai: Piramal Pharma Limited Consumer Products Division (CPD), has announced the launch of its D2C platform, Wellify.in.
It is an exclusive, one-stop shop for all the health and wellness brand offerings by the company, and is expected to contribute 10 percent of the e-commerce business in terms of revenue by end of FY24.
The platform shall provide consumers' access to its entire range of products across more than 20 brands along with all the new offerings that the company is going to launch in the future. The platform would offer products across various categories such as health & wellness, beauty, baby care & toys, and women's intimate range.
The platform will offer free home delivery, no minimum order value, and delightful offers which will enable rise in daily orders.
Wellify is designed to offer personalised experience to the users powered by advanced technology as Piramal CPD has invested in Martech tools to offer superlative experience to its consumers
Nitish Bajaj, CEO, and Piramal Consumer Product Division commented, "E-commerce has exploded in the country and has been a major growth engine for our business as well. With the launch of our D2C platform, Wellify.in, we are looking at bolstering our e-commerce capabilities by reaching out to our customers directly with quality products, customised offerings, and multiple delivery options. We have heavily invested in e-commerce in the last two years which is poised for significant growth and is expected to contribute to 25 percent of our overall revenue in the next 3 years".
Piramal Pharma's India Consumer Products Division's portfolio comprises 21 brands with offerings spanning across multiple categories. It aims to be among the top three over-the-counter (OTC) product companies in India. Over the last two years, the business has invested significantly in various growth levers. Piramal CPD has been focusing on celebrity-led campaigns, expanding its distribution network, and leveraging e-commerce extensively.
Piramal Pharma Limited (PPL), a subsidiary of Piramal Enterprises Limited, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 14 global facilities and a global distribution network in over 100 countries.
PPL includes an integrated contract development and manufacturing (CDMO) business, Complex hospital generics business, and India Consumer Products business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market.
In October 2020, PPL received 20 percent strategic growth investment from the Carlyle Group.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.